Introduction/Overview
Natural products have always been an important source of innovative drug discovery, and their structural diversity and wide range of biological activities provide unique molecular frameworks and lead compounds for the treatment of various diseases. Among numerous medicinal plants, plants of the Ligustrum genus have attracted much attention due to their long history of traditional medicinal use, often used to treat inflammation, infections, and diseases related to oxidative stress. Thick Ligustrum lucidum glycoside N, as a glycoside compound isolated from thick Ligustrum lucidum leaves, has gradually entered the field of pharmacological researchers in recent years due to its significant antioxidant activity and potential anti-tumor effects. Preliminary studies have shown that this compound can not only effectively eliminate free radicals and inhibit hemolysis induced by oxidative stress, but also show the potential of multi-target regulation in the in vitro model of breast cancer and other malignant tumors. This article aims to systematically review the chemical properties, plant sources, pharmacological activities, molecular mechanisms of action, and medicinal properties of Ligustrum lucidum glycoside N, in order to provide comprehensive academic references for the in-depth research and future development of this compound.
Chemical structure and physicochemical properties
The chemical name of Ligurobustoside N is Ligurobustoside N, and its CAS registration number is 583058-07-5. Structurally, it belongs to the phenylethanoid glycoside class, which is a characteristic active ingredient in plants of the Ligustrum genus. Its molecular formula is C ∝₄ H ₄₂ O ₁₉, with a molecular weight of 754.7350 Da. This structure typically contains a phenylethanol glycoside, which is linked to multiple sugar groups (such as glucose, xylose, etc.) through glycosidic bonds, forming a large polar molecule with multiple hydroxyl groups. This structural characteristic directly determines its physicochemical properties: the calculated lipid water partition coefficient LogP value is about 0.0302, indicating its strong hydrophilicity; The topologically polar surface area is as high as 283.9800 Å ², further confirming the presence of a large number of polar groups (such as hydroxyl groups) on its molecular surface. These parameters collectively indicate its good water solubility, with a calculated value of approximately 4.4707 mg/L. The higher polarity and water solubility mean that its distribution in the body may be more inclined towards plasma and extracellular fluid, making it difficult to penetrate the rich lipid bilayer blood-brain barrier, and predicting its blood-brain barrier permeability as "low". In addition, preliminary pharmacological risk assessment showed that the hERG channel inhibition risk was "no", and the Ames test result was 0.0, indicating that it may have low risks of cardiac and genetic toxicity, laying a preliminary safety foundation for subsequent development.
Plant sources and extraction methods
The main source of Ligustrum lucidum glycoside N is the dried leaves of Ligustrum lucidum, a plant in the genus Ligustrum in the family Rhinoceros. Thick and robust Ligustrum lucidum, as an evergreen shrub or small tree, is widely distributed in southwestern China and other regions. Its leaves are often recorded as medicinal in folk culture. The isolation and purification of robust Ligustrum lucidum glycoside N from plant materials usually follow the classic process of natural product chemistry. Firstly, the dried and crushed leaves are subjected to extraction or reflux extraction using polar solvents such as methanol, ethanol, or methanol water mixed solutions to fully extract the phenolic glycosides present. Subsequently, crude extract was obtained by vacuum concentration. Crude extracts are often initially enriched using macroporous adsorption resin column chromatography, with gradient elution using ethanol water solutions of different concentrations. Phenylethanolic glycosides are typically enriched in the middle to high polarity sites (such as the 30% -70% ethanol elution sites). After obtaining a fraction rich in target components, various chromatographic techniques such as silica gel column chromatography, reverse phase silica gel column chromatography, and high-performance liquid chromatography are further used for repeated separation and purification. Among them, semi preparative or preparative reverse phase high performance liquid chromatography is a key step in obtaining high-purity and robust N monomers of Ligustrum lucidum, often using methanol water or acetonitrile water as the mobile phase. Structural identification was carried out through spectroscopic techniques such as nuclear magnetic resonance and mass spectrometry to ultimately confirm its chemical structure. Optimizing the extraction and separation process to improve yield is a prerequisite for ensuring its subsequent pharmacological research and application development.
Pharmacological activity research
At present, the pharmacological activities of ligustroside N are mainly focused on antioxidant and anti-tumor fields, and the anti-tumor activity of breast cancer is the most prominent.
1. antioxidant activity This is the most basic activity reported for Ligustrum lucidum glycoside N. Research has shown that this compound can effectively scavenge free radicals such as DPPH and ABTS, and exhibits significant reducing ability. More importantly, in an in vitro red blood cell oxidative hemolysis model, robust Ligustrum lucidum glycoside N can significantly inhibit hemolytic reactions induced by AAPH (a water-soluble free radical initiator). AAPH can continuously generate alkoxy free radicals in a 37 ℃ aqueous solution, attacking red blood cell membrane lipids and causing membrane integrity damage and hemolysis. The inhibitory effect of ligustroside N shows that it can effectively quench free radicals and protect cell membrane from oxidative damage, which provides an experimental basis for its potential application in anti-aging, anti-inflammatory and prevention of oxidative stress related diseases (such as atherosclerosis).
2. Anti breast cancer activity A number of in vitro studies have revealed that ligustroside robusta N has proliferation inhibitory and apoptosis promoting effects on many breast cancer cell lines (such as MCF-7, MDA-MB-231, etc.). Its anti-tumor effect is not achieved through a single cytotoxic pathway, but exhibits the characteristics of multi-target and multi pathway regulation. The experiment shows that ligustroside N can induce cell cycle arrest (such as G0/G1 phase or G2/M phase) of breast cancer cells, and activate caspase cascade reaction, leading to apoptosis. In addition, the compound can also inhibit the migration and invasion of breast cancer cells, suggesting that it may have anti metastasis potential. These broad cellular effects suggest that their mechanism of action involves complex signaling network regulation.
Mechanism of action and molecular targets
Based on the existing research, the mechanism of action of ligustroside N against breast cancer involves the regulation of multiple key signaling pathways and molecular targets, and the preliminarily related targets include AMPK, MCL1, BCL2, NOTCH1, STAT3, ESR2, TYR, ABCB1, ABCG2, PRKCA, etc.
* Regulating cell apoptosis and survival pathways Thick Ligustrum lucidum glycoside N may inhibit cell growth and promote autophagy or apoptosis by activating AMPK (PRKAA1), a cellular energy sensor, and suppressing synthetic metabolic pathways such as mTOR. At the same time, it can downregulate the expression of anti apoptotic proteins Bcl-2 and Mcl-1, disrupt mitochondrial membrane potential, promote cytochrome C release, and activate endogenous apoptotic pathways. Inhibition of the STAT3 signaling pathway is also one of its important mechanisms. The sustained activation of STAT3 is closely related to tumor cell proliferation, survival, and immune escape. Ligustrum lucidum N may exert a pro apoptotic effect by inhibiting the phosphorylation of STAT3 and the transcription of downstream target genes such as Mcl-1 and Bcl-2.
* Intervention in cell proliferation and differentiation signaling Notch1 signaling pathway plays a key role in the maintenance of breast cancer stem cells and tumorigenesis. Ligustroside N may inhibit the dryness and proliferation of breast cancer cells by inhibiting the activation of Notch1 and affecting the expression of its downstream target genes Hes1, Hey1, etc. In addition, its potential regulation of estrogen receptor beta (ESR2) also deserves attention, which may affect the growth of hormone dependent breast cancer.
* Affects drug efflux and resistance Chemotherapy resistance in breast cancer is often associated with the overexpression of ATP binding cassette transporters (such as ABCB1/P-gp, ABCG2/BCRP), which can pump chemotherapeutic drugs out of cells and reduce intracellular drug concentration. Studies have shown that ligustroside robusta N may have the potential to inhibit the function of these efflux pumps, thereby reversing the multidrug resistance of breast cancer cells and enhancing the efficacy of conventional chemotherapy drugs.
* Other potential targets: Its potential effect on protein kinase C α (PRKCA) and tyrosinase (TYR) may be related to tumor cell signal transduction and melanin synthesis respectively, but its specific role in breast cancer needs further clarification.
To sum up, ligustroside N can jointly inhibit the proliferation of breast cancer cells, promote their apoptosis, inhibit metastasis and possibly reverse drug resistance through multi target and multi pathway synergy, showing the unique advantages of "multi target" natural products.
Evaluation of drug properties and pharmacokinetics
Although Ligustrum lucidum glycoside N has demonstrated good biological activity in vitro, its potential as a drug candidate molecule still requires systematic pharmacological evaluation and pharmacokinetic studies.
* Physicochemical and Preliminary ADMET Properties As mentioned earlier, its high TPSA, low LogP, and high water solubility meet the solubility requirements in the three principles of generic drugs, but its extremely high polarity may pose challenges to its oral bioavailability. Polar molecules are often difficult to penetrate the intestinal epithelial cell membrane through passive diffusion and may become substrates for intestinal efflux transporters (such as P-gp), which are then pumped into the ileal lumen. The low permeability of the blood-brain barrier limits its use in central nervous system diseases, but may have little impact on peripheral system diseases (such as breast cancer). The absence of hERG inhibition and Ames mutagenicity risk are positive early safety signals.
* Pharmacokinetic prediction and challenges Based on its structure, it can be inferred that the pharmacokinetic behavior of Ligustrum lucidum glycoside N in vivo may have the following characteristics: (1)absorb Oral absorption may be poor and bioavailability may be low. It may be necessary to improve through structural modifications (such as prodrug preparation) or by using non oral administration routes (such as injection). （2）distribution Mainly distributed in blood and extracellular fluid, tissue permeability, especially the ability to enter the interior of solid tumors, requires experimental verification. （3）Metabolism As a glycoside compound, it is likely to be hydrolyzed by β - glucosidase and other enzymes in the gut microbiota and/or liver, removing glycosides to produce aglycones. The physicochemical properties and activities of aglycones may be completely different from those of the prototype compounds, which is both a challenge (low concentration of the prototype drug) and a new opportunity (aglycones may be the truly effective form). （4）excretion The prototype drug and its metabolites may be mainly excreted from urine through the kidneys.
At present, there have been no detailed reports on the in vivo pharmacokinetic studies of the N-system of robust Ligustrum lucidum (such as the absorption, distribution, metabolism, and excretion processes in rats or mice), which is a key blank area for its development.
Clinical application prospects and prospects
As a natural glycoside with multi target anti breast cancer activity, ligustroside N has broad clinical application prospects, but it has a long way to go, and needs to be explored from multiple dimensions:
1. Development of anti-tumor candidate drugs: The primary direction is to continue to deepen the research on its mechanism of anti breast cancer, and use gene knockdown/overexpression, reporter gene, molecular docking, surface plasmon resonance and other technologies to clarify its direct interaction with the above key targets. On this basis, a systematic pharmacodynamic evaluation was carried out in vivo to establish a model of breast cancer transplanted tumor or transgenic mice, and to verify its anti-tumor effect and safety in vivo. In response to its drug weakness (such as poor oral absorption), reasonable structural optimization can be carried out to improve its lipid solubility and membrane permeability while retaining the pharmacophore.
2. Application as a chemotherapy sensitizer Given its potential to reverse multidrug resistance mediated by ABC transporters, the combination of Ligustrum lucidum glycoside N or its derivatives with existing chemotherapy drugs (such as doxorubicin and paclitaxel) is expected to reduce chemotherapy dosage, alleviate toxic side effects, and overcome drug resistance, and has important clinical translational value.
3. Expansion in antioxidant stress-related diseases Its powerful antioxidant and cell protective effects should not be ignored. Exploring its therapeutic effects in pathological models closely related to oxidative stress, such as non-alcoholic fatty liver disease, myocardial ischemia-reperfusion injury, and neurodegenerative diseases.
4. In depth study of its metabolism and active forms in the body Systematic ADME research must be carried out as soon as possible to clarify its in vivo metabolic profile and identify the activity of major metabolites, especially aglycones. It is possible that the prototype drug is a 'prodrug', and the real active molecule is its metabolite, which will completely change the development strategy.
5. Pharmaceutical research To improve its delivery efficiency, new drug delivery systems such as nanoparticles, liposomes, polymer micelles, etc. can be explored to enhance their targeting, stability, and bioavailability.
Conclusion
Ligustroside N is a phenylethanoid glycoside with significant antioxidant and anti breast cancer potential isolated from the traditional medicinal plant Ligustrum robustum. It inhibits the proliferation of breast cancer cells, induces apoptosis and may reverse drug resistance by regulating AMPK, STAT3, Bcl-2 family, Notch1 and other signal pathways, showing the advantage of multi target effect. Although its clear molecular interaction mechanism and in vivo pharmacological and pharmacokinetic data still need to be enriched, and its highly polar physicochemical properties pose challenges to drug development, these challenges also point to the direction of future research. With the continuous progress of natural product chemistry, molecular pharmacology and drug design technology, through in-depth mechanism analysis, reasonable structural modification and innovative preparation development of ligustroside N, it is expected to transform it from a potential phytochemical to a candidate drug or lead compound for breast cancer treatment or adjuvant treatment, providing new options for tumor treatment.
